Insulin Resistance and Reward

Obesity Clinical Trial

— IRRSO  

Official title:

Insulin Resistance and Reward Signaling in Obesity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02241603
• Other study ID #: CLNB-004-13F
• Status: Completed
• Phase: Phase 2
• Start date: November 17, 2014
• Est. completion date: July 1, 2020

Study information

• Verified date: July 2020
• Source: VA Office of Research and Development
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Obesity is a common problem in the Veteran population as at least 1 in 3 Veterans are obese. When obese people eat food they have less response in areas of the brain that sense pleasure (reward). Decreased pleasure response to food predicts future weight gain. It is not known if this poor brain response is reversible or why obese people's brains respond this way. Insulin in the brain regulates the brain's sensing of pleasure. As people gain weight the function of insulin becomes impaired. The investigators will study if impaired function of insulin is related to a poor brain response to food and if this brain response predicts voluntary intake of food and response to a diet. The investigators will also study if improving the function of insulin with weight loss improves the brain response. These studies will improve the understanding as to why weight loss is difficult and inform us if improving insulin signaling is a potential way to treat obesity.

Description:

The current research proposal will investigate the relationship of insulin sensitivity to brain reward signaling. In most obese individuals, insulin signaling is impaired (insulin resistance). Preclinical animal studies suggest that insulin resistance in brain regions important for reward contribute to overeating. This proposal aims to test these hypotheses in humans and to determine if these characteristics are pertinent to clinical outcomes (food intake and weight loss). In humans increased body mass index (BMI) and weight gain occur with decreased food consumption-induced neural activation (consummatory reward) in the caudate of the dorsal striatum. It has been speculated that diminished consummatory reward causes overeating and prevents weight loss, however, this hypothesis has not been directly tested. Further, mechanisms for impaired food consumption-induced neural activation in obesity have not been investigated.

The primary research outcomes of the proposed study are: 1) insulin sensitivity determined by hyperinsulinemic euglycemic clamp, 2) food consumption-induced neural activation as determined by blood-oxygen dependent functional magnetic resonance imaging (BOLD fMRI) scanning, 3) caloric intake at a buffet meal, and 4) weight loss during a weight loss intervention. Based on screening and baseline outcome assessments half of participants will be enrolled in a weight loss intervention and then repeat outcomes measures after intervention. Others will only complete baseline outcome measures. Secondary measures of the study include whole brain activation analyses, neuroendocrine hormone measurement at the time of imaging, psychometric measures including eating behaviors and personality characteristics, and measures of reward sensitivity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 59
• Est. completion date: July 1, 2020
• Est. primary completion date: July 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 60 Years

Eligibility

Inclusion Criteria:

• Age 25-60yoa, inclusive.

• BMI 30.0 and 45.0 kg/m2, inclusive.

• Normal visual acuity with correction.

• Able to travel regularly to the St. Louis VA and Washington University for research visits.

• Completed signed informed consent form.

Exclusion Criteria:

• Current or history of significant psychiatric disease, including Binge Eating Disorder (BED).

• Current or history of significant substance abuse or extended use of tobacco.

• Contraindications for MRI (e.g., pregnancy, claustrophobia, pacemaker, circumference > 54 inches, weight > 400 lbs, etc.);

• Significant cardiovascular, pulmonary, renal, liver, neurologic, or metabolic disease.

• Diabetes mellitus.

• Significant anemia.

• Treatment with a medication the affects insulin sensitivity.

• Treatment with centrally acting medications.

• Frequent shift work.

• Significant in-mobility or unable to lay on back still for 1 hour.

• History of bariatric surgery.

• Food allergies/ intolerance that would prevent completing study.

• Symptoms concerning for untreated active mental health disease

Related Conditions & MeSH terms

• Insulin Resistance
• Obesity

Intervention

Behavioral:
• Weight loss
Obese Veterans will undergo dietary education for weight loss or weight maintenance

Locations

Country	Name	City	State
United States	St. Louis VA Medical Center John Cochran Division, St. Louis, MO	Saint Louis	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
VA Office of Research and Development	Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	food consumption-induced neural activation	food consumption-induced neural activation as determined by blood-oxygen dependent functional magnetic resonance imaging (BOLD fMRI) scanning	~4-9months